

# Andrew B Lassman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1142724/publications.pdf>

Version: 2024-02-01

111  
papers

6,166  
citations

236925

25  
h-index

74163

75  
g-index

114  
all docs

114  
docs citations

114  
times ranked

8137  
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 1963-1972.	1.6	3,222
2	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543
3	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 492-516.	1.6	261
4	Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3861-3867.	1.6	159
5	Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). <i>Neuro-Oncology</i> , 2015, 17, 992-998.	1.2	116
6	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Neuro-Oncology</i> , 2017, 19, now208.	1.2	109
7	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1209-1217.	2.3	108
8	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 627-642.	3.3	102
9	Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 695-707.	27.6	90
10	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , The, 2018, 19, e20-e32.	10.7	87
11	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019, 21, 106-114.	1.2	84
12	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now257.	1.2	80
13	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 403-426.	1.6	67
14	Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 838-847.	1.2	60
15	Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic. <i>Neuro-Oncology</i> , 2020, 22, 912-917.	1.2	59
16	Preparing a neurology department for SARS-CoV-2 (COVID-19). <i>Neurology</i> , 2020, 94, 886-891.	1.1	50
17	Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHt): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	46
18	Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1195-1203.	0.8	45

#	ARTICLE	IF	CITATIONS
19	Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 137, 303-311.	2.9	43
20	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 797-804.	0.8	40
21	Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?. <i>Neuro-Oncology</i> , 2015, 17, 1022-1028.	1.2	39
22	Phase 2 and biomarker study of trebananib, an angiopoietin-1 blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. <i>Cancer</i> , 2018, 124, 1438-1448.	4.1	38
23	A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. <i>Investigational New Drugs</i> , 2020, 38, 1784-1795.	2.6	38
24	Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. <i>Neuro-Oncology</i> , 2023, 25, 339-350.	1.2	35
25	Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery. <i>Journal of Neuro-Oncology</i> , 2015, 124, 507-514.	2.9	33
26	Infigratinib in Patients with Recurrent Gliomas and <i>EGFR</i> Alterations: A Multicenter Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2270-2277.	7.0	30
27	A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 452-460.	7.0	29
28	Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines*. <i>Neuro-Oncology</i> , 2019, 21, 424-427.	1.2	27
29	A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 146, 79-89.	2.9	26
30	Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?. <i>CNS Oncology</i> , 2015, 4, 341-346.	3.0	25
31	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 205-210.	2.9	24
32	Comparison of Biomarker Assays for <i>EGFR</i> : Implications for Precision Medicine in Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 3259-3265.	7.0	24
33	ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM). <i>Neuro-Oncology</i> , 2019, 21, vi17-vi17.	1.2	23
34	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, 2539-2545.	1.6	23
35	Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines. <i>Journal of Clinical Oncology</i> , 2019, 37, 1130-1135.	1.6	22
36	Magnetic Resonance Imaging-Based Screening for Asymptomatic Brain Tumors: A Review. <i>Oncologist</i> , 2019, 24, 375-384.	3.7	22

#	ARTICLE	IF	CITATIONS
37	Current usage of tumor treating fields for glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa069.	0.7	20
38	Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma. <i>Practical Radiation Oncology</i> , 2016, 6, 306-314.	2.1	17
39	Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2502-2502.	1.6	17
40	Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery. <i>Journal of Neuro-Oncology</i> , 2016, 127, 103-110.	2.9	16
41	Outcomes of gamma knife radiosurgery, bi-modality & tri-modality treatment regimens for patients with one or multiple brain metastases: the Columbia University Medical Center experience. <i>Journal of Neuro-Oncology</i> , 2015, 122, 399-408.	2.9	15
42	Chemotherapy Treatment and Trials in Low-Grade Gliomas. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 103-109.	1.7	15
43	NovoTTF: where to go from here?. <i>Neuro-Oncology</i> , 2017, 19, 605-608.	1.2	14
44	Individualized screening trial of innovative glioblastoma therapy (INSIGHt).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2079-TPS2079.	1.6	14
45	A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2021-2021.	1.6	13
46	Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?. <i>Seminars in Radiation Oncology</i> , 2015, 25, 203-209.	2.2	12
47	CMET-22. INTRATHECAL (IT) TRAZTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY. <i>Neuro-Oncology</i> , 2018, 20, vi58-vi58.	1.2	9
48	Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2003-2003.	1.6	9
49	Efficacy and safety of selinexor in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2005-2005.	1.6	9
50	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. <i>Neuro-Oncology</i> , 2022, 24, 1219-1229.	1.2	9
51	Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3615-3615.	1.6	8
52	A Modern Radiotherapy Series of Survival in Hispanic Patients with Glioblastoma. <i>World Neurosurgery</i> , 2016, 88, 260-269.	1.3	7
53	Clinical Reasoning: Transient speech deficits in a patient with history of medulloblastoma. <i>Neurology</i> , 2018, 91, e1196-e1201.	1.1	7
54	Sequencing and curation strategies for identifying candidate glioblastoma treatments. <i>BMC Medical Genomics</i> , 2019, 12, 56.	1.5	7

#	ARTICLE	IF	CITATIONS
55	Success at Last: A Molecular Factor That Informs Treatment. <i>Current Oncology Reports</i> , 2013, 15, 47-55.	4.0	6
56	Factorial clinical trials: a new approach to phase II neuro-oncology studies. <i>Neuro-Oncology</i> , 2015, 17, 174-176.	1.2	6
57	Local control and overall survival for adjuvant stereotactic radiosurgery in patients with residual or recurrent disease. <i>Journal of Neuro-Oncology</i> , 2018, 136, 281-287.	2.9	6
58	Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas. <i>Neurology</i> , 2022, 98, .	1.1	6
59	Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSideã,,ç Assay. <i>Clinical Breast Cancer</i> , 2022, 22, e457-e462.	2.4	6
60	ACTR-33. INFIGRATINIB (BGJ398) IN PATIENTS WITH RECURRENT GLIOMAS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) ALTERATIONS: A MULTICENTER PHASE II STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi20-vi20.	1.2	5
61	Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuzizumab mafadotin. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab102.	0.7	5
62	Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2542-2542.	1.6	5
63	Effect of therapeutic pressure on stability of EGFR amplification in glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2033-2033.	1.6	5
64	GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS2579-TPS2579.	1.6	5
65	Biomarkers in NOA-04: another piece to the puzzle. <i>Neuro-Oncology</i> , 2016, 18, 1467-1469.	1.2	4
66	Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?. <i>Neuro-Oncology</i> , 2021, 23, 347-349.	1.2	4
67	Cerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11549-11549.	1.6	4
68	CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2021, 23, vi59-vi59.	1.2	4
69	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. <i>Neuro-Oncology</i> , 2022, 24, 331-357.	1.2	4
70	Evaluation of tumor responses and overall survival in patients with recurrent glioblastoma (GBM) from a phase IIa trial of a CMV vaccine immunotherapeutic candidate (VBI-1901).. <i>Journal of Clinical Oncology</i> , 2022, 40, 2014-2014.	1.6	4
71	ACTR-13. FINAL RESULTS WITH CHEMORADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMORS FROM NRG ONCOLOGY/RTOG 9402. <i>Neuro-Oncology</i> , 2019, 21, vi15-vi15.	1.2	3
72	Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3005-3005.	1.6	3

#	ARTICLE	IF	CITATIONS
73	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2022, 40, TPS2078-TPS2078.	1.6	3
74	RT-36 * ONCOLOGIC OUTCOME OF HISPANIC PATIENTS WITH GLIOBLASTOMA TREATED WITH RADIOTHERAPY. Neuro-Oncology, 2014, 16, v195-v195.	1.2	2
75	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2021, 39, TPS2074-TPS2074.	1.6	2
76	Ipilimumab for recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2014, 32, e13026-e13026.	1.6	2
77	A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2016, 34, 2077-2077.	1.6	2
78	Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2019, 37, 2048-2048.	1.6	2
79	Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2020, 38, 2540-2540.	1.6	2
80	Comparison of attitudes and beliefs about cancer clinical trial enrollment between physicians, research staff, and cancer patients.. Journal of Clinical Oncology, 2019, 37, 170-170.	1.6	2
81	ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA. Neuro-Oncology, 2019, 21, vi20-vi21.	1.2	1
82	Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?. Neuro-Oncology, 2020, 22, 1058-1059.	1.2	1
83	Repeat Radiation in the Brain: Managing Patients With Locally Recurrent Glioma. Seminars in Radiation Oncology, 2020, 30, 218-222.	2.2	1
84	Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas.. Journal of Clinical Oncology, 2021, 39, e14037-e14037.	1.6	1
85	Hospitalization burden and end-of-life (EOL) care in elderly patients with glioblastoma (GBM).. Journal of Clinical Oncology, 2021, 39, 31-31.	1.6	1
86	Phase II trial of bevacizumab and temozolomide for upfront treatment of elderly patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2012-2012.	1.6	1
87	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro-Oncology, 2022, 24, 358-383.	1.2	1
88	RT-35 * ELAPSED DAYS AFTER RADIOTHERAPY FOR GLIOBLASTOMA. Neuro-Oncology, 2014, 16, v195-v195.	1.2	0
89	ACTR-06. THE TOCA 7 STUDY: PHASE 1B STUDY OF TOCA 511, A LIVE GAMMA RETROVIRUS, AND TOCA FC, AN EXTENDED-RELEASE FORMULATION OF 5-FLUOROCYTOSINE COMBINED WITH STANDARD OF CARE IN NEWLY DIAGNOSED HIGH GRADE GLIOMA (NCT02598011). Neuro-Oncology, 2016, 18, vi2-vi2.	1.2	0
90	INNV-06. FACTORS INFLUENCING RECEPTIVITY TO CLINICAL RESEARCH IN AN URBAN NEURO-ONCOLOGY PRACTICE. Neuro-Oncology, 2018, 20, vi139-vi139.	1.2	0

#	ARTICLE	IF	CITATIONS
91	QOLP-05. THE EFFECT OF RESILIENCE ON QUALITY OF LIFE IN PATIENTS WITH HIGH GRADE GLIOMAS AND THEIR CAREGIVERS. <i>Neuro-Oncology</i> , 2018, 20, vi215-vi215.	1.2	0
92	PATH-17. HYPERPROGRESSIVE DISEASE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS TREATED WITH IMMUNE CHECKPOINT INHIBITORS OR CYTOTOXIC THERAPIES. <i>Neuro-Oncology</i> , 2019, 21, vi146-vi146.	1.2	0
93	PATH-57. MRI-LOCALIZED BIOPSIES REVEAL HISTOPATHOLOGIC HETEROGENEITY IN POST-TREATMENT RECURRENT HIGH-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi156-vi156.	1.2	0
94	QOLP-32. PATTERNS OF CARE AT END OF LIFE IN PATIENTS WITH GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi204-vi205.	1.2	0
95	ATIM-26. INTERIM RESULTS OF THE EXTENSION PHASE OF A PHASE I/IIA TRIAL OF A THERAPEUTIC CMV VACCINE AGAINST RECURRENT GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2019, 21, vi7-vi7.	1.2	0
96	TMOD-14. RADIOGRAPHIC, STIMULATED RAMAN HISTOLOGIC, AND MULTIPLEXED RNA-SEQUENCING ANALYSIS OF POST-TREATMENT RECURRENT HIGH-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi265-vi265.	1.2	0
97	Digital measurement of functional status of patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2016-2016.	1.6	0
98	A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2071-TPS2071.	1.6	0
99	A meta-analysis of antiangiogenic therapy for glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2047-2047.	1.6	0
100	Outcomes of Gamma Knife radiosurgery, bimodality, and trimodality treatment regimens for patients with one or multiple brain metastases: The Columbia University Medical Center experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13032-e13032.	1.6	0
101	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology/RTOG 0525 and 0825.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2007-2007.	1.6	0
102	Synergistic effect of reirradiation and PD-1 inhibitors in recurrent high-grade gliomas.. <i>Journal of Clinical Oncology</i> , 2017, 35, 105-105.	1.6	0
103	Hyperprogressive disease in patients with recurrent high grade gliomas treated with immune checkpoint inhibitors or other therapies.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13575-e13575.	1.6	0
104	Molecular predictors of response to selinexor in recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 2565-2565.	1.6	0
105	Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3567-3567.	1.6	0
106	CTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT) EXPERIENCE. <i>Neuro-Oncology</i> , 2021, 23, vi68-vi69.	1.2	0
107	CTNI-27. SINGLE AGENT ACTIVITY OF ONC201 IN NON-MIDLINE H3 K27M-MUTANT DIFFUSE GLIOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi65-vi65.	1.2	0
108	CTNI-17. A PHASE 1 WITH DOSE EXPANSION/PHASE 2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi62-vi63.	1.2	0

#	ARTICLE	IF	CITATIONS
109	NCOG-27. STATUS AS A CLINICAL TRIAL PARTICIPANT AND OUTCOME IN IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi157-vi158.	1.2	0
110	NCMP-05. LEFT BASAL GANGLIA/INTERNAL CAPSULE GLIOBLASTOMA WITH MEMORY LOSS FROM CONTRALATERAL RADIATION INDUCED VASCULOPATHIES. Neuro-Oncology, 2021, 23, vi148-vi148.	1.2	0
111	Rapidly adapting the clinical research environment at an NCI-designated comprehensive cancer center to the COVID-19 pandemic.. Journal of Clinical Oncology, 2022, 40, e13534-e13534.	1.6	0